Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus gemcitabine and cisplatin or carboplatin for muscle-invasive bladder urothelial carcinoma
ChiCTR2100050763Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Sep 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, gemcitabine, cisplatin and carboplatin in transitional cell carcinoma of the bladder (TCC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Bladder preservation rate. Started Sep 2021; status: recruiting.
02
Drugs
tislelizumabgemcitabinecisplatincarboplatin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2100050763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050763.